

W H O T e c h n i c a l R e p o r t S e r i e s

# The Selection and Use of Essential Medicines

---

Report of the WHO Expert Committee, 2011  
(including the 17th WHO Model List of Essential Medicines  
and the 3rd WHO Model List of Essential Medicines for Children)

*This report contains the collective views of an international group of experts and  
does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health  
Organization**

# Contents

<b>Executive summary</b>	vii
<b>List of participants of the 18th Expert Committee on the Selection and Use of Essential Medicines</b>	xi
<b>Declaration of interests of Members of the 18th Expert Committee on the Selection and Use of Essential Medicines</b>	xiii
<b>1. Introduction</b>	1
<b>2. Open session</b>	3
<b>3. Review of Report of supplementary session, January 2010: Other antiviral medicines</b>	5
<b>4. General items</b>	9
1: IUPHAR – report on clinical pharmacology	9
2: How to develop a national essential medicines list	9
3: Rational use of medicines – future strategies and directions	10
4: Updated list of missing drug formulations for HIV treatment	10
5: Guidance on the extemporaneous preparation of medicines for children (draft for consultation)	11
6: Review of proposed medical module for inpatient management of severe acute malnutrition with medical complications in children	11
7: Review of application process	12
8: Essential medicines that can be used in neonates	12
<b>5. Applications only for paediatric medicines</b>	13
<b>Section 2: Analgesics, antipyretic medicines, non-steroidal anti-inflammatory medicines (NSAIDs), medicines used to treat gout, and disease-modifying agents in rheumatoid disorders (DMARDs)</b>	13
Section 2.1: Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)	13
Ibuprofen (review) – Children	13
Section 2.2: Opioid analgesics	14
Codeine (deletion) – Children	14
Section 2.4: Disease-modifying agents used in rheumatoid disorders	15
Methotrexate, sulfasalazine, azathioprine, leflunomide, hydroxychloroquine, mycophenolate, and cyclosporine (review) – Children	15
Methotrexate	16
Hydroxychloroquine	20
Leflunomide, sulfasalazine, azathioprine, cyclosporine, mycophenolate	20
<b>Section 4: Antidotes and other substances used in poisonings</b>	21
Section 4.2: Specific	21
Oral iron chelation therapy (review) – Children	21
Oral lead chelation therapy (review) – Children	23
Sodium calcium edetate and penicillamine (review) – Children	23

2,3-dimercapto-1-propanesulfonic acid (DMPS)	23
Penicillamine	24
Sodium calcium edetate and dimercaprol	24
Succimer (new application) – Children	26
<b>Section 6: Anti-infective medicines</b>	27
Neglected tropical diseases (review) – Children	27
Section 6.1: Anthelmintics	27
Section 6.2: Antifilarial medicines	28
Section 6.3: Antischistosomal and antitremitode medicines	28
Section 6.5: Antiprotozoal medicines	28
Section 6.5.1: Anti-amoebic and anti-giardiasis medicines	28
Section 6.5.2: Antileishmaniasis medicines	29
Section 6.2: Antibacterial medicines	38
Fluoroquinolones (review) – Children	38
<b>Section 8: Antineoplastic agents, immunosuppressives and medicines used in palliative care (review) – Children</b>	39
Section 8.2: Cytotoxic medicines	43
Imatinib (inclusion) – Children and adolescents	43
Section 8.4: Medicines used in palliative care	44
<b>Section 10: Medicines affecting the blood</b>	44
Section 10.2: Medicines affecting coagulation	44
Antithrombotic (review) – Children	44
<b>Section 15: Disinfectants and antiseptics</b>	46
Chlorhexidine (change of formulation) – Children	46
<b>Section 16: Diuretics</b>	48
Mannitol (review) – Children	48
Spironolactone (review) – Children	48
<b>Section 17: Gastrointestinal medicines</b>	49
Section 17.5: Medicines used in diarrhoea	49
Section 17.5.2: Medicines for diarrhoea in children	49
Zinc sulfate (new formulation) – Children	49
<b>Section 18: Hormones</b>	50
Section 18.5: Insulins and other antidiabetic agents	50
Review of the use of oral hypoglycaemic agents in children (review) – Children	50
<b>6. Applications for the 17th Model List and the 3rd EMLc</b>	53
<b>Section 1: Anaesthetics</b>	53
Section 1.1: General anaesthetics and oxygen	55
Ether (re-instatement)	55
Promethazine (deletion) – Adults and children	56
Propofol (inclusion)	57
Section 1.3: Preoperative medication and sedation for short-term procedures	58
Midazolam (inclusion)	58
<b>Section 4: Antidotes and other substances used in poisonings</b>	59
Section 4.2: Specific	59
DL-methionine (deletion)	59
<b>Section 6: Anti-infective medicines</b>	60
Section 6.2: Antibacterial medicines	60

Section 6.2.2: Other antibacterial medicines	60
Gatifloxacin (inclusion)	60
Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim (new formulation)	61
Sulfamethoxazole + trimethoprim (new formulation)	62
Section 6.4: Antiviral medicines	63
Section 6.4.2: Antiretroviral medicines	63
Section 6.4.2.2: Non-nucleoside reverse transcriptase inhibitors	63
Etravirine (inclusion)	63
Section 6.4.2.3: Protease inhibitors	64
Darunavir (inclusion)	64
Section 6.4.2.4: Integrase inhibitors (new section heading)	65
Raltegravir (inclusion)	65
Section 6.5: Antiprotozoal medicines	65
Section 6.5.2: Antileishmaniasis medicines	65
Miltefosine (inclusion) – Adults and children	65
Section 6.5.3: Antimalarial medicines	67
Artesunate + amodiaquine fixed-dose combination (inclusion) – Adults and children	67
Dihydroartemisinin + piperaquine (inclusion) – Adults and children	69
Pyronaridine + artesunate fixed-dose combination (inclusion) – Adults and children	70
<b>Section 8: Antineoplastic agents, immunosuppressives, and medicines used in palliative care</b>	71
Section 8.2: Cytotoxic medicines	71
Paclitaxel (inclusion); Docetaxel (inclusion)	71
<b>Section 10: Medicines affecting the blood</b>	72
Section 10.2: Medicines affecting coagulation	72
Tranexamic acid (inclusion)	72
<b>Section 12: Cardiovascular medicines</b>	74
Bisoprolol (inclusion) – square box	74
<b>Section 13: Dermatological medicines (topical)</b>	76
Dermatological medicines (review) – Adults and children	76
<b>Section 17: Gastrointestinal medicines</b>	77
Section 17.1: Antacids and other anti-ulcer medicines	77
Aluminium hydroxide (deletion)	77
Magnesium hydroxide (deletion)	77
Review of treatment of <i>Helicobacter pylori</i> in adults and children	78
Section 17.5: Medicines used in diarrhoea	80
Section 17.5.3: Antidiarrhoeal (symptomatic) medicines in adults	80
Codeine (deletion); Loperamide (inclusion)	80
<b>Section 18: Hormones, other endocrine medicines and contraceptives</b>	81
Section 18.4: Estrogens	81
Ethinylestradiol (deletion)	81
Section 18.7: Progestogens	81
Norethisterone and medroxyprogesterone acetate (deletion)	81
Section 18.5: Insulins and other antidiabetic agents	83
Glucagon (inclusion)	83
Review of the evidence comparing insulin (human or animal) with analogue insulins (review)	84

<b>Section 22: Oxytocics and anti-oxytocics</b>	85
Section 22.1: Oxytocics	85
Misoprostol (new formulation)	85
Oxytocin (change of formulation)	88
<b>Section 24: Psychotherapeutic medicines</b>	89
Psychotherapeutic medicines (review of section headings)	89
<b>Section 25: Medicines acting on the respiratory tract</b>	90
Section 25.1: Anti-asthmatic medicines and medicines for chronic obstructive pulmonary disease	90
Salbutamol (deletion)	90
New section: Haemaglobinopathies	91
Hydroxycarbamide (inclusion)	91
<b>7. Summary of recommendations</b>	93
17th WHO Model List of Essential Medicines	93
Additions to Model List	93
Deletions from Model List	95
Changes to sections	96
Amended dosage strength and form	97
Rejected applications	97
3rd Essential Medicines List for children	98
Additions to EMLc	98
Deletions from EMLc	99
Changes to sections	100
Amended dosage strength and form	101
Rejected medicines	101
Recommendations for reviews	102
Medicines marked for consideration of deletion at the next meeting	103
Missing essential medicines	103
<b>Annex 1: 17th WHO Model List of Essential Medicines</b>	105
<b>Annex 2: 3rd WHO Model List of Essential Medicines for Children</b>	149
Appendix: Essential medicines that can be used in neonates	182
<b>Annex 3: The Anatomical Therapeutic Chemical (ATC) Classification System</b>	185
<b>Annex 4: Alphabetical list of essential medicines (with ATC classification code numbers)</b>	209
<b>Annex 5: Report of the Supplementary Meeting of the Expert Committee on the Selection and Use of Essential Medicines</b>	219
List of participants	219
Declaration of interests	220
Introduction	221
Section 6.4.3: Other antiviral medicines	221
Amantadine and rimantadine, oseltamivir, zanamivir (inclusion)	221
Evidence summary	223
Considerations of the Expert Committee	224
<b>References</b>	227